0001209191-20-036981.txt : 20200616
0001209191-20-036981.hdr.sgml : 20200616
20200616162947
ACCESSION NUMBER: 0001209191-20-036981
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200616
FILED AS OF DATE: 20200616
DATE AS OF CHANGE: 20200616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILSON TROY EDWARD
CENTRAL INDEX KEY: 0001589597
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 20966792
MAIL ADDRESS:
STREET 1: C/O KURA ONCOLOGY, INC.
STREET 2: 3033 SCIENCE PARK RD, SUITE 220
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10975 N. TORREY PINES RD.,
STREET 2: #150
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10975 N. TORREY PINES RD.,
STREET 2: #150
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-16
0
0001599901
Avidity Biosciences, Inc.
RNA
0001589597
WILSON TROY EDWARD
C/O AVIDITY BIOSCIENCES, INC.
10975 N. TORREY PINES RD., SUITE 150
LA JOLLA
CA
92037
1
0
0
0
Common Stock
2020-06-16
4
C
0
189042
A
805301
I
By family trust
Common Stock
189618
D
Common Stock
35553
I
By trust FBO Child 1
Common Stock
35553
I
By trust FBO Child 2
Common Stock
11851
I
By trust FBO Child 3
Common Stock
11851
I
By trust FBO Child 4
Series A Preferred Stock
2020-06-16
4
C
0
254907
D
Common Stock
120837
0
I
By family trust
Series B Preferred Stock
2020-06-16
4
C
0
35374
D
Common Stock
16769
0
I
By family trust
Series C Preferred Stock
2020-06-16
4
C
0
108504
D
Common Stock
51436
0
I
By family trust
The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering.
Includes 59,256 shares subject to repurchase by the Issuer, which shares will vest in 15 equal monthly installments beginning on June 29, 2020.
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
2020-06-16